
Research peptides
Melanotan I
Melanotan I is the earlier name for afamelanotide, [Nle4, D-Phe7]-alpha-MSH, a synthetic 13-amino-acid analogue of alpha-melanocyte-stimulating hormone that was first synthesized in 1980.
- Container
- Glass vial, crimp seal, flip-top cap
- Storage
- -20 °C, desiccated
- Paperwork
- Lot certificate (HPLC + mass spec) shown before you pay
Lot certificates
You’ll see American Peptides on the lab’s copy. They’re our supplier.
- 10 mg, lot MT110-0318: 99.80% purity (RP-HPLC), 10.78 mg measured, identity confirmed by mass spec. Issued 2026-04-03 by Bioviridian Inc.. Verify certificate COA3394
Our vials are filled from lots made by our supplier, American Peptides, and tested by Bioviridian Inc.The laboratory’s original certificate lists American Peptides as the vendor. Look up the code at bioviridians.com to check it.
What researchers study it for
- Erythropoietic protoporphyria
- Skin pigmentation and eumelanin
- Vitiligo
- Polymorphic light eruption and solar urticaria
How it is thought to work
Afamelanotide is a melanocortin receptor agonist that binds predominantly to the melanocortin-1 receptor. Receptor signaling increases production of eumelanin in the skin, independently of exposure to sunlight or artificial UV light. This mechanism is well established and is described in the FDA label.
Where the research stands
Approved drug (as afamelanotide, Scenesse). Afamelanotide is approved in the EU (2014) and the USA (2019) for adults with erythropoietic protoporphyria, supported by randomized, placebo-controlled trials. That approval applies to the licensed product only.
Sources
- Langendonk JG, et al. (2015). Afamelanotide for Erythropoietic Protoporphyria. The New England Journal of Medicine.
- Dorr RT, et al. (2000). Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans. Photochemistry and Photobiology.
- Minder EI, et al. (2017). Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clinical Pharmacokinetics.
- Wu J, Cotliar R. (2021). Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. Journal of Drugs in Dermatology.
For laboratory research use only. Not a drug, food, supplement or cosmetic; not for human or veterinary use. Nothing on this page is medical advice or a usage guide.
